tp53 antibody d0 1  (Santa Cruz Biotechnology)

Journal: Translational Cancer Research

Article Title: Silencing PPA1 promotes the survival of non-small cell lung cancer A549 cells under glucose-starved conditions

doi: 10.21037/tcr-2025-1106

Figure Lengend Snippet: Silencing PPA1 enhances A549 survival under glucose-free condition. (A) CCK-8 detection of cell viability of the A549-shCtrl, A549-shPPA1-1, and A549-shPPA1-2 cell lines under glucose starvation. (B) Colony formation of A549-shCtrl, A549-shPPA1-1, and A549-shPPA1-2 cell lines under glucose-starved conditions (crystal violet staining; magnification, ×1). (C) Cell cycle analysis by flow cytometry in A549-shCtrl, A549-shPPA1-1, and A549-shPPA1-2 cells under glucose starvation. (D) Western blotting detection of the expression of proliferative proteins in PPA1-silenced A549 cells under glucose starvation. *, P<0.05; **, P<0.01; ***, P<0.001; ****, P<0.0001, compared with the shCtrl group; N=3. shPPA1-1 vs. shCtrl: p21-0h, P=0.004; CDK2-0h, P<0.001; Ki-67-0h, P<0.001; p53-0h, P=0.001; p21-24h, P=0.03; CDK2-24h, P=0.008; Ki-67-24h, P=0.003; p53-24h, P<0.001; shPPA1-2 vs. shCtrl: p21-0h, P<0.001; CDK2-0h, P<0.001; Ki-67-0h, P<0.001; p53-0h, P=0.03; p21-24h, P<0.001; CDK2-24h, P=0.007; Ki-67-24h, P=0.01; p53-24h, P=0.001. shCtrl group: empty vector control group; shPPA1-1 and shPPA1-2 groups: PPA1-silencing groups. PE-A, phycoerythrin-area; PPA1, inorganic pyrophosphatase 1.

Article Snippet: PPA1 antibody (B-8), beta-actin antibody (C4), and TP53 antibody (D0-1) were purchased from Santa Cruz Biotechnology (Dallas, TX, USA), Ki-67 antibody was purchased from Abcam (Cambridge, UK).

Techniques: CCK-8 Assay, Staining, Cell Cycle Assay, Flow Cytometry, Western Blot, Expressing, Plasmid Preparation, Control

Journal: Cancer cell international

Article Title: Influence of TP53 and CDH1 genes in hepatocellular cancer spheroid formation and culture: a model system to understand cancer cell growth mechanics.

doi: 10.1186/s12935-016-0318-1

Figure Lengend Snippet: Fig. 5 Live growth capture: spheroids in all 5 lines imaged at 1 and 3 days post seeding. The spheroid morphologies are distinct depending on the TP53 status. The TP53-wt cell lines, C3A and HepG2 form large spheroids with a smooth boundary edge. TP53-null cell line of Hep3B forms compact, intermediate-sized spheroids. The TP53-mutant cell lines, SNU-387 and SNU-475, form small sized spheroids with a rougher boundary edge. The size and shape patterns are consistent over the 10 day incubation period in multiple replicates

Article Snippet: Cells were later incubated with D0-1 TP53 antibody (Santa Cruz, Dallas, TX; sc-126) or anti E-Cadherin antibody (Abcam, Cambridge, UK; ab76055), washed and then followed immediately by Alexa Fluor® 488 secondary antibody (LifeTechnologies; A31620).

Techniques: Mutagenesis, Incubation

Journal: Cancer cell international

Article Title: Influence of TP53 and CDH1 genes in hepatocellular cancer spheroid formation and culture: a model system to understand cancer cell growth mechanics.

doi: 10.1186/s12935-016-0318-1

Figure Lengend Snippet: Fig. 9 Quantitative real-time PCR: mRNA gene expression of TP53 and CDH1 genes in all five cell lines. Relative expression normalized to the value of the HepG2 (wt) cell line. a TP53 gene expression: The TP53-wt cell lines, C3A and HepG2 show intermediate levels of expression. There is overexpression of TP53 in the SNU-475 mutant cell line (see text). Minimal to no expression is observed in SNU-387 and TP53-null Hep3B cell lines. Similar patterns of expression is observed in both 2-D and 3-D cell cultures. b CDH1 gene expression: The TP53-null cell line, Hep3B shows maximal expression of CDH1 mRNA in 2-D and 3-D cultures. The TP53 wild-type cell lines show intermediate expression, while the TP53-mutants show mini- mal to absent expression of CDH1. ***indicates a significant difference between the compared cell lines at a 99 % level statistical significance using a paired t test (P-value ≤ 0.01)

Article Snippet: Cells were later incubated with D0-1 TP53 antibody (Santa Cruz, Dallas, TX; sc-126) or anti E-Cadherin antibody (Abcam, Cambridge, UK; ab76055), washed and then followed immediately by Alexa Fluor® 488 secondary antibody (LifeTechnologies; A31620).

Techniques: Real-time Polymerase Chain Reaction, Gene Expression, Expressing, Over Expression, Mutagenesis

Journal: Cancer cell international

Article Title: Influence of TP53 and CDH1 genes in hepatocellular cancer spheroid formation and culture: a model system to understand cancer cell growth mechanics.

doi: 10.1186/s12935-016-0318-1

Figure Lengend Snippet: Fig. 10 Western blotting in 2-D and 3-D cell cultures: a maximal TP53 protein expression is noted in TP53 mutant SNU-475 while maximal CDH1 expression is observed in the TP53-null cell line, Hep3B (see text for explanation). The patterns are consistent in 2-D and 3-D cultures. An additional band is observed in SNU-475 in 2-D which probably represents the β and γ isoforms of TP53 corresponding to 48 and 47 kDa sizes respectively. GAPDH was used a loading control. b Band intensities for TP53 (left) and CDH1 (right) normalized to corresponding GAPDH control. 2D and 3D ratios show some slight variation due to the inherent variability associated with quantification of western blot intensities

Article Snippet: Cells were later incubated with D0-1 TP53 antibody (Santa Cruz, Dallas, TX; sc-126) or anti E-Cadherin antibody (Abcam, Cambridge, UK; ab76055), washed and then followed immediately by Alexa Fluor® 488 secondary antibody (LifeTechnologies; A31620).

Techniques: Western Blot, Expressing, Mutagenesis, Control

Journal: BMC Cancer

Article Title: Derivation and characterization of matched cell lines from primary and recurrent serous ovarian cancer

doi: 10.1186/1471-2407-12-379

Figure Lengend Snippet: Detection of various keratins (KRT) by Western blot (A) to confirm the epithelial origin of cell lines. B) p53 and HER2 expression by Western blot. Note the absence of detectable expression of p53 for the 3133 cell lines. Beta actin was used as a loading control.

Article Snippet: Western Blot (WB) and immunohistochemistry (IHC) analyses were performed using the following antibodies: beta actin (AB 6276, Abcam, Cambridge UK); TP53 (D0-1) (sc-126, Santa Cruz Biotechnology, CA, USA); HER2/ErbB2/Neu (C-18) (sc-284, Santa Cruz Biotechnology); Keratin 7 Ab-2 (MS-1352-P, NeoMarker, Medicorp, Qc, Canada); Keratin 8 Ab-4 (MS-997-P, NeoMarker, Medicorp); Keratin 18 (DC-10) (sc-6259, Santa Cruz Biotechnology); Keratin 19 Ab-1 (MS198-P, Lab Vision Corp., CA, USA), and Keratin 20 (SPM140) (ab15205, Abcam).

Techniques: Western Blot, Expressing, Control

Journal: BMC Cancer

Article Title: Derivation and characterization of matched cell lines from primary and recurrent serous ovarian cancer

doi: 10.1186/1471-2407-12-379

Figure Lengend Snippet: Immunohistochemical analysis of paraffin embedded solid tumors (TOV1369, TOV2295(R), TOV3133D and TOV3133G) with keratin markers, p53 and HER20. Nuclei are counterstained with hematoxylin, and images are at x400 magnification. Positive staining was seen for all solid tumors for each keratin tested, and HER2. Note the lower expression detected for p53 in TOV3133D and TOV3133G. Note that the (t) designation denotes that the primary tumor tissue was investigated.

Article Snippet: Western Blot (WB) and immunohistochemistry (IHC) analyses were performed using the following antibodies: beta actin (AB 6276, Abcam, Cambridge UK); TP53 (D0-1) (sc-126, Santa Cruz Biotechnology, CA, USA); HER2/ErbB2/Neu (C-18) (sc-284, Santa Cruz Biotechnology); Keratin 7 Ab-2 (MS-1352-P, NeoMarker, Medicorp, Qc, Canada); Keratin 8 Ab-4 (MS-997-P, NeoMarker, Medicorp); Keratin 18 (DC-10) (sc-6259, Santa Cruz Biotechnology); Keratin 19 Ab-1 (MS198-P, Lab Vision Corp., CA, USA), and Keratin 20 (SPM140) (ab15205, Abcam).

Techniques: Immunohistochemical staining, Staining, Expressing

Journal: BMC Cancer

Article Title: Derivation and characterization of matched cell lines from primary and recurrent serous ovarian cancer

doi: 10.1186/1471-2407-12-379

Figure Lengend Snippet: Cell growth characteristics, IC 50 values and mutation status of ovarian cancer cell lines derived either at initial diagnosis (TOV1369, OV2295, TOV3133G, TOV3133D), or relapse after chemotherapy (OV1369(R2), OV2295(R2), TOV2295(R), OV3133(R), OV3133(R2))

Article Snippet: Western Blot (WB) and immunohistochemistry (IHC) analyses were performed using the following antibodies: beta actin (AB 6276, Abcam, Cambridge UK); TP53 (D0-1) (sc-126, Santa Cruz Biotechnology, CA, USA); HER2/ErbB2/Neu (C-18) (sc-284, Santa Cruz Biotechnology); Keratin 7 Ab-2 (MS-1352-P, NeoMarker, Medicorp, Qc, Canada); Keratin 8 Ab-4 (MS-997-P, NeoMarker, Medicorp); Keratin 18 (DC-10) (sc-6259, Santa Cruz Biotechnology); Keratin 19 Ab-1 (MS198-P, Lab Vision Corp., CA, USA), and Keratin 20 (SPM140) (ab15205, Abcam).

Techniques: Mutagenesis, Derivative Assay, Biomarker Discovery, Migration, Injection